{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:42:51Z","timestamp":1772620971727,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016132","name":"Gouvernement Wallon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blocking programmed cell death protein 1 (PD-1) has become a standard cancer immunotherapy, increasingly used in kidney, liver, or heart transplant recipients who develop skin cancer or hepatocellular carcinoma, despite the increased risk of graft failure or rejection. The mechanism of action of PD-1 blockade relies on stimulating CD8+ T cell activity, but its impact on humoral immunity in general and on alloimmunization in particular remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the impact on anti-PD-1 treatment on alloimmunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effect of anti-PD-1 treatment on the generation of anti-HLA (Human Leucocyte Antigen) antibodies was investigated in 72 patients with non-small cell lung cancer vaccinated with an allogeneic plasmacytoid dendritic cell line (PDC*line; six weekly injections), with or without pembrolizumab administered every three weeks. The kinetics and functionality of the anti-HLA generated were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results show that 51.4% of the patients developed anti-HLA antibodies, primarily dependent on the vaccine dose. In 60% of cases, the antibody response appeared after the sixth injection, peaked after one month, and then gradually declined over two years. Anti-HLA class II antibodies appeared earlier than class I antibodies. Functional assays demonstrated complement-dependent cytotoxicity against allogeneic B lymphocytes and PDC*line cells in the serum of some patients, with no difference related to treatment. PD-1 blockade did not alter the magnitude, kinetics, or cytotoxic potential of the vaccine-induced humoral response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results indicate that, during allogeneic human vaccination, PD-1 signaling exerts a limited effect on antibody production and effector function, suggesting a more complex regulatory role in humoral immunity than previously thought.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1763434","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:15Z","timestamp":1772602875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Severine","family":"Planel","sequence":"first","affiliation":[{"name":"R&D Department, PDC*line Pharma France","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Vayssi\u00e8re","sequence":"additional","affiliation":[{"name":"R&D Department, PDC*line Pharma France","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Maggipinto","sequence":"additional","affiliation":[{"name":"G.M. Consultant Company","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Leplus","sequence":"additional","affiliation":[{"name":"R&D Department, PDC*line Pharma France","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Laulagnier","sequence":"additional","affiliation":[{"name":"R&D Department, PDC*line Pharma France","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Renard","sequence":"additional","affiliation":[{"name":"R&D and Clinical Departments, PDC*line Pharma Belgique","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francoise","family":"Myster","sequence":"additional","affiliation":[{"name":"R&D and Clinical Departments, PDC*line Pharma Belgique","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Gerard","sequence":"additional","affiliation":[{"name":"Human Leukocyte Antigen (HLA) Laboratory, Etablissement Fran\u00e7ais du Sang (EFS) Rhone-Alpes Auvergne","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingel","family":"Demedts","sequence":"additional","affiliation":[{"name":"Pulmonary Diseases, AZ Delta Campus Rumbeke","place":["Roeselare, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristof","family":"Cuppens","sequence":"additional","affiliation":[{"name":"Pulmonology and Thoracic Oncology Department, Jessa Hospital","place":["Hasselt, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvire","family":"Pons-Tostivint","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Nantes University Hospital","place":["Nantes, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Wauters","sequence":"additional","affiliation":[{"name":"Respiratory Oncology Unit (Pulmonology), University Hospitals Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Borm","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Sibille","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centre Hospitalier Universitaire de Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Colinet","sequence":"additional","affiliation":[{"name":"Pneumology Department, Grand H\u00f4pital de Charleroi, Site Notre Dame","place":["Charleroi, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willemijn S. M. E.","family":"Theelen","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, Netherlands Cancer Institute","place":["Amsterdam, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonne","family":"Biesma","sequence":"additional","affiliation":[{"name":"Pulmonology, Jeroen Bosch Hospital","place":["\u2018s-Hertogenbosch, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Van De Kerkhove","sequence":"additional","affiliation":[{"name":"Clinical Study Centre, Vitaz campus Sint-Niklaas Moerland","place":["Sint-Niklaas, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Buchmeier","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Kliniken der Stadt Koln gGmbH","place":["K\u00f6ln, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike C.","family":"Althoff","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Department, Universit\u00e4tsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universit\u00e4t)","place":["Frankfurt Am Main, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Derijcke","sequence":"additional","affiliation":[{"name":"Pulmonology: Thoracic Oncology, AZ Groeninge, Campus Kennedylaan","place":["Kortrijk, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[{"name":"Thoracic Oncology, Service d'Hospitalo-Universitaire de Pneumologie et Pneumo-Oncologie (SHUPP), Centre Hospitalier Universitaire (CHU) Grenoble-Alpes","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Cantero","sequence":"additional","affiliation":[{"name":"R&D and Clinical Departments, PDC*line Pharma Belgique","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Chaperot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), team Translational Immunology and Immunotherapy in Chronic Disease","place":["Grenoble, France"]},{"name":"Recherche et D\u00e9veloppement, Etablissement Fran\u00e7ais du Sang Auvergne-Rh\u00f4ne-Alpes","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Saas","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), team Translational Immunology and Immunotherapy in Chronic Disease","place":["Grenoble, France"]},{"name":"Recherche et D\u00e9veloppement, Etablissement Fran\u00e7ais du Sang Auvergne-Rh\u00f4ne-Alpes","place":["Grenoble, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Skrzypski","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Vansteenkiste","sequence":"additional","affiliation":[{"name":"Respiratory Oncology Unit (Pulmonology), University Hospitals Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl","family":"Plumas","sequence":"additional","affiliation":[{"name":"R&D Department, PDC*line Pharma France","place":["Grenoble, France"]},{"name":"R&D and Clinical Departments, PDC*line Pharma Belgique","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229\u221239","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.esmogo.2023.100037","article-title":"Comparative efficacy of PD-1 blockade in patients with dMMR\/MSI-H metastatic colorectal or gastric cancer: a global retrospective study","volume":"3","author":"Mazzoli","year":"2024","journal-title":"ESMO Gastrointest Oncol 1 mars"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394\u2212401","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune checkpoint inhibitors and the risk of allograft rejection: A comprehensive analysis on an emerging issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: A systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2457\u221265","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review","volume":"20","author":"D\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae061","article-title":"Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients","volume":"17","author":"Van Meerhaeghe","year":"2024","journal-title":"Clin Kidney J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.3389\/ti.2024.13322","article-title":"Immune checkpoint inhibitor therapy for kidney transplant recipients - A review of potential complications and management strategies","volume":"37","author":"Barbir","year":"2024","journal-title":"Transpl Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"677\u2212704","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"467\u221277","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1553\u221262","DOI":"10.1084\/jem.192.11.1553","article-title":"Cxc chemokine receptor 5 expression defines follicular homing T cells with B cell helper function","volume":"192","author":"Schaerli","year":"2000","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1545\u221252","DOI":"10.1084\/jem.192.11.1545","article-title":"Follicular B helper T cells express cxc chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production","volume":"192","author":"Breitfeld","year":"2000","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5099\u2212108","DOI":"10.4049\/jimmunol.179.8.5099","article-title":"Role of CXCR5 and CCR7 in follicular th cell positioning and appearance of a programmed cell death gene-1High germinal center-associated subpopulation1","volume":"179","author":"Haynes","year":"2007","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2592\u2212602","DOI":"10.4049\/jimmunol.1701231","article-title":"Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function","volume":"200","author":"Sage","year":"2018","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5648\u221255","DOI":"10.4049\/jimmunol.1003161","article-title":"Blockade of B7-H1 (Programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells","volume":"186","author":"Hams","year":"2011","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001187","article-title":"A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy","volume":"8","author":"S\u00e1nchez-Alonso","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"127\u221238","DOI":"10.1016\/j.intimp.2018.10.045","article-title":"PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction","volume":"66","author":"Zhang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"206\u221210","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1183\u221292","DOI":"10.1038\/s41590-022-01274-3","article-title":"PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine","volume":"23","author":"Herati","year":"2022","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840207","article-title":"Patterns of peripheral blood B-cell subtypes are associated with treatment response in patients treated with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study","volume":"13","author":"Barth","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3808\u221216","DOI":"10.1200\/JCO.21.02986","article-title":"Antibody response to COVID-19 mRNA vaccine in patients with lung cancer after primary immunization and booster: reactivity to the SARS-coV-2 WT virus and omicron variant","volume":"40","author":"Valanparambil","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"105844","DOI":"10.1016\/j.esmoop.2025.105844","article-title":"Innovative therapeutic cancer vaccine PDC\u2217lung01 with or without anti-PD-1: an open-label, dose-escalation phase I\/II study in non-small-cell lung cancer","volume":"10","author":"Vansteenkiste","year":"2025","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2395\u2212406","DOI":"10.1038\/jid.2012.152","article-title":"HLA-A*0201 + Plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients","volume":"132","author":"Aspord","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/ijms24031897","article-title":"A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands the tumor-specific CD8+ T cells of lung cancer patients","volume":"24","author":"Hannani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"161\u22128","DOI":"10.1097\/CCO.0000000000000815","article-title":"Harnessing dendritic cells for innovative therapeutic cancer vaccines","volume":"34","author":"Plumas","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1738812","DOI":"10.1080\/2162402X.2020.1738812","article-title":"An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial","volume":"9","author":"Charles","year":"2020","journal-title":"OncoImmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"597\u2212603","DOI":"10.1097\/TP.0000000000002351","article-title":"Comparison of two luminex single-antigen bead flow cytometry assays for detection of donor-specific antibodies after renal transplantation","volume":"103","author":"Bertrand","year":"2019","journal-title":"Transplantation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1428\u221233","DOI":"10.1038\/sj.leu.2401517","article-title":"Quantification of cellular adhesion molecules on Malignant B cells from non-Hodgkin\u2019s lymphoma","volume":"13","author":"Jacob","year":"1999","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29\u221236","DOI":"10.1016\/S0022-1759(99)00087-3","article-title":"Standardisation of a procedure for quantifying surface antigens by indirect immunofluorescence","volume":"228","author":"Smith","year":"1999","journal-title":"J Immunol Methods"},{"key":"B30","doi-asserted-by":"publisher","first-page":"111\u221223","DOI":"10.1016\/S0022-1759(97)00138-5","article-title":"Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods","volume":"209","author":"Lecoeur","year":"1997","journal-title":"J Immunol Methods"},{"key":"B31","doi-asserted-by":"publisher","first-page":"949\u221254","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01712","article-title":"Characterization of the C1q-binding ability and the igG1\u20134 subclass profile of preformed anti-HLA antibodies by solid-phase assays","volume":"10","author":"Navas","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1132\u221248","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: A decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"246\u221259","DOI":"10.1111\/imr.12411","article-title":"T follicular regulatory cells","volume":"271","author":"Sage","year":"2016","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1215\u221226","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"New Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp8843","article-title":"Divergent immune responses to commensal bacteria bearing distinct motility signatures","volume":"10","author":"Duck","year":"2025","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:18Z","timestamp":1772602878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1763434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1763434"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1763434","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1763434"}}